Login to Your Account

MARQUEE Terminates Early

ArQule Tumbles on Survival Miss in Lung Cancer Study

By Catherine Shaffer
Staff Writer

Wednesday, October 3, 2012
Shares of ArQule Inc., of Woburn, Mass., plummeted 56.3 percent Tuesday following news that an independent data safety monitoring committee had terminated its Phase III MARQUEE trial of ARQ 197 in nonsquamous non-small-cell lung cancer (NSCLC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription